Bệnh lý thần kinh ngoại biên ở bệnh nhân HIV tại châu Phi cận Sahara không thành công với liệu pháp điều trị đầu tay và phản ứng với liệu pháp ART thứ hai trong thử nghiệm EARNEST

Arenas-Pinto A, Bhaskaran K, Dunn D, Weller IV (2008) The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial. Antivir Ther 13(2):289–295

Biraguma J, Rhoda A (2012) Peripheral neuropathy and quality of life of adults living with HIV/AIDS in the Rulindo district of Rwanda. SAHARA J 9(2):88–94

Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W et al (2006) Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 61(9):791–794

Cettomai D, Kwasa J, Kendi C, Birbeck GL, Price RW, Bukusi EA et al (2010) Utility of quantitative sensory testing and screening tools in identifying HIV-associated peripheral neuropathy in Western Kenya: pilot testing. PLoS One 5(12):e14256

Chen H, Clifford DB, Deng L, Wu K, Lee AJ, Bosch RJ et al (2013) Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. J Neurovirol 19(6):557–564

Cherry CL, Affandi JS, Imran D, Yunihastuti E, Smyth K, Vanar S et al (2009) Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology 73(4):315–320

Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA et al (1999) Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 52(3):607–613

Collins MA, Neafsey EJ, Zou JY (2000) HIV-I gpI20 neurotoxicity in brain cultures is prevented by moderate ethanol pretreatment. Neuroreport 11(6):1219–1222

Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L et al (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16(1):75–83

Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, Collier AC et al (2005) Clinical validation of the NeuroScreen. J Neurovirol 11(6):503–511

Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC et al (2008) Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 64(5):566–572

Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T et al (2010) Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 67(5):552–558

Evans SR, Ellis RJ, Chen H, Yeh TM, Lee AJ, Schifitto G et al (2011) Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 25(7):919–928

Evans D, Takuva S, Rassool M, Firnhaber C, Maskew M (2012) Prevalence of peripheral neuropathy in antiretroviral therapy naive HIV-positive patients and the impact on treatment outcomes—a retrospective study from a large urban cohort in Johannesburg, South Africa. J Neurovirol 18(3):162–171

Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ (2010) Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS 24(Suppl 5):S29–36

Kamerman PR, Wadley AL, Cherry CL (2012) HIV-associated sensory neuropathy: risk factors and genetics. Curr Pain Headache Rep 16(3):226–236

Kampira E, Kumwenda J, van Oosterhout JJ, Dandara C (2013) Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in malawian adults on stavudine containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 63(5):647–652

Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD (2005) Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 40(1):148–157

Luma HN, Tchaleu BC, Doualla MS, Temfack E, Sopouassi VN, Mapoure YN et al (2012) HIV-associated sensory neuropathy in HIV-1 infected patients at the Douala General Hospital in Cameroon: a cross-sectional study. AIDS Res Ther 9(1):35

Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, Levitt NS et al (2010) HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 41(5):599–606

Marra CM, Boutin P, Collier AC (1998) Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings. Neurology 51(6):1678–1681

Mehta SA, Ahmed A, Laverty M, Holzman RS, Valentine F, Sivapalasingam S (2011) Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis 53(5):490–496

Nakamoto BK, McMurtray A, Davis J, Valcour V, Watters MR, Shiramizu B et al (2010) Incident neuropathy in HIV-infected patients on HAART. AIDS Res Hum Retrovir 26(7):759–765

Paik IJ, Kotler DP (2011) The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 25(3):469–478

Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A et al (2014) Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 371(3):234–247

Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A et al (2006) Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 59(5):816–824

Shaikh A, Bentley A, Kamerman PR (2013) Symptomatology of peripheral neuropathy in an African language. PLoS One 8(5):e63986

van Buuren S, Boshuizen HC, Knook DL (1999) Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18(6):681–694

van der Watt JJ, Harrison TB, Benatar M, Heckmann JM (2011) Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. Int J Tuberc Lung Dis 15(6):722–728

van Oosterhout JJ, Mallewa J, Kaunda S, Chagoma N, Njalale Y, Kampira E et al (2012) Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One 7(7):e42029

Wadley AL, Cherry CL, Price P, Kamerman PR (2011) HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J Pain Symptom Manag 41(4):700–706

Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P et al (2009) Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 48(11):1617–1623

Wright E, Brew B, Arayawichanont A, Robertson K, Samintharapanya K, Kongsaengdao S et al (2008) Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology 71(1):50–56